Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (DE:9LB)
FRANKFURT:9LB
Earnings Data
Report Date
Aug 29, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.04Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -14.48%
|Next Earnings Date:Aug 29, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive momentum with significant sales growth, operational efficiency, and strategic expansions in global markets. While there are challenges related to net loss and exchange rate impacts, the overall outlook is optimistic with a solid financial position and promising developments in the CAR-T space.Company Guidance
During Legend Biotech's Q1 2025 earnings call, the company provided several key metrics and guidance. Net trade sales for CARVYKTI reached approximately $369 million, reflecting a 135% year-over-year increase. The company treated over 6,000 patients with CARVYKTI, maintaining its status as the strongest CAR-T launch to date. Legend Biotech aims for CARVYKTI to achieve operational breakeven by the end of 2025 and anticipates company-wide profitability in 2026, excluding unrealized foreign exchange gains or losses. The first quarter also saw a significant 137% year-over-year growth in collaboration revenue. With a cash position of approximately $1 billion, Legend continues to invest in expanding manufacturing capacities in Belgium and New Jersey and advancing its pipeline programs. The company reported an adjusted net loss of $27 million, down from an operating loss of $118 million in the prior year, and noted a 63% gross margin on net product sales. These efforts align with Legend's strategic priorities to enhance operational efficiency and achieve long-term growth.CARVYKTI Net Trade Sales Surge
Net trade sales for CARVYKTI reached approximately $369 million, marking a 135% increase year-over-year.
Expansion in Global Markets
Strong performance outside the U.S. with sales reaching $51 million, more than double compared to the same period last year, driven by expansion in Germany, Switzerland, Austria, and Brazil.
Operational Efficiency Improvements
Operating loss reduced by more than half from $118 million to $51 million year-over-year due to operational efficiency and disciplined expense management.
Manufacturing Success Rate
Achieved a 97% manufacturing success rate and 95% timely delivery, with a decreasing median turnaround time now at 30 days.
Cash Reserves and Financial Health
Maintained a strong cash position of approximately $1 billion, supporting operations until profitability anticipated in 2026.
Regulatory Approvals and Clinical Advancements
CARVYKTI was approved in Australia for second line plus setting, and overall survival was added to the EMA label.
DE:9LB Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:9LB Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | €29.00 | €27.60 | -4.83% |
Mar 11, 2025 | €31.20 | €33.80 | +8.33% |
Nov 12, 2024 | €37.40 | €37.60 | +0.53% |
Aug 09, 2024 | €52.00 | €50.50 | -2.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Legend Biotech Corporation (DE:9LB) report earnings?
Legend Biotech Corporation (DE:9LB) is schdueled to report earning on Aug 29, 2025, TBA Not Confirmed.
What is Legend Biotech Corporation (DE:9LB) earnings time?
Legend Biotech Corporation (DE:9LB) earnings time is at Aug 29, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Legend Biotech Corporation stock?
The P/E ratio of Legend Biotech is N/A.
What is DE:9LB EPS forecast?
DE:9LB EPS forecast for the fiscal quarter 2025 (Q2) is -0.09.